Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets

Cancer Gene Therapy

Volumn 23, Issue 2-3, 2016, Pages 48-53

  Huang, Q X ^a   Cui, J Y ^b   Ma, H ^b   Jia, X M ^a   Huang, F L ^a   Jiang, L X ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TROPOMYOSIN; ELAV LIKE PROTEIN 2; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PYRUVATE KINASE; PYRUVATE KINASE M2; TUMOR MARKER; UNCLASSIFIED DRUG; CARRIER PROTEIN; COL1A2 PROTEIN, HUMAN; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; MEMBRANE PROTEIN; SPP1 PROTEIN, HUMAN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TPM1 PROTEIN, HUMAN; TROPOMYOSIN;

ARTICLE; BILE DUCT CARCINOMA; BILE SECRETION; CANCER GROWTH; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; GENE ONTOLOGY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIPID ABSORPTION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BILE DUCT NEOPLASMS; CELL CULTURE; CHOLANGIOCARCINOMA; GENE EXPRESSION PROFILING; GENETICS; INFORMATION PROCESSING; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CARCINOGENESIS; CARRIER PROTEINS; CELL CYCLE; CELLS, CULTURED; CHOLANGIOCARCINOMA; COLLAGEN TYPE I; DATASETS AS TOPIC; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; OSTEOPONTIN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN INTERACTION MAPS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID HORMONES; TROPOMYOSIN; UP-REGULATION;

EID: 84950266677     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.66     Document Type: Article

References (40)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. New Engl J Med 1999; 341: 1368-1378.
2. Wu T, Han C, Lunz JG 3rd, Michalopoulos G, Shelhamer JH, Demetris AJ. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology 2002; 36: 363-373.
3. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472-477.
4. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
5. Chang KY, Chang JY, Yen Y. Increasing incidence of intrahepatic cholangiocarci-noma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 2009; 7: 423-427.
6. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S et al. Cho-langiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463-473.
7. Patel T. Increasing incidence and mortality of primary intrahepatic cholangio-carcinoma in the United States. Hepatology 2001; 33: 1353-1357.
8. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995; 109: 1612-1617.
9. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangio-carcinoma. Histopathology 1999; 35: 230-240.
10. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706-712.
11. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006; 116: 1843-1852.
12. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002; 36: 439-450.
13. Sugawara H, Yasoshima M, Katayanagi K, Kono N, Watanabe Y, Harada K et al. Relationship between interleukin-6 and proliferation and differentiation in cho-langiocarcinoma. Histopathology 1998; 33: 145-153.
14. Seol MA, Chu IS, Lee MJ, Yu GR, Cui XD, Cho BH et al. Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma. BMC Cancer 2011; 11: 78.
15. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2013; 41: D991-D995.
16. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 2007; 8: R183.
17. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29.
18. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
19. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 2003; 31: 258-261.
20. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41: D808-D815.
21. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011; 27: 431-432.
22. Ikenaga N, Liu SB, Sverdlov DY, Yoshida S, Nasser I, Ke Q et al. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol 2015; 185: 325-334.
23. Yeh CN, Weng WH, Lenka G, Tsao LC, Chiang KC, Pang ST et al. cDNA microarray pro fi ling of rat cholangiocarcinoma induced by thioacetamide. Mol Med Rep 2013; 8: 350-360.
24. Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K et al. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 2014; 5: 8202-8210.
25. Yang W, Wang X, Zheng W, Li K, Liu H, Sun Y. Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma. Int J Oncol 2013; 42: 690-698.
26. Verma A, Matta A, Shukla NK, Deo SV, Gupta SD, Ralhan R. Clinical significance of mannose-binding lectin-associated serine protease-2 expression in esophageal squamous cell carcinoma. Int J Cancer 2006; 118: 2930-2935.
27. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685-696.
28. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 1997; 17: 3153-3156.
29. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD et al. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077-5082.
30. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH et al. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 2012; 18: 4037-4043.
31. Zhan C, Shi Y, Lu C, Wang Q. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer. Dis Esophagus 2013; 26: 746-753.
32. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K et al. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001; 91: 67-75.
33. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH et al. Overexpression of osteo-pontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98: 119-127.
34. Hass HG, Nehls O, Jobst J, Frilling A, Vogel U, Kaiser S. Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cho-langiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol 2008; 14: 2501-2510.
35. Choi C, Kim D, Kim S, Jeong S, Song E, Helfman DM. From skeletal muscle to cancer: insights learned elucidating the function of tropomyosin. J Struct Biol 2012; 177: 63-69.
36. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003; 22: 6194-6203.
37. Pawlak G, McGarvey TW, Nguyen TB, Tomaszewski JE, Puthiyaveettil R, Malkowicz SB et al. Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. Int J Cancer 2004; 110: 368-373.
38. Yager ML, Hughes JA, Lovicu FJ, Gunning PW, Weinberger RP, O'Neill GM. Functional analysis of the actin-binding protein, tropomyosin 1, in neuroblastoma. Br J Cancer 2003; 89: 860-863.
39. Bharadwaj S, Prasad GL. Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. Cancer Lett 2002; 183: 205-213.
40. Schevzov G, Whittaker SP, Fath T, Lin JJ, Gunning PW. Tropomyosin isoforms and reagents. Bioarchitecture 2011; 1: 135-164.